Artiva Q3 net loss $21.5M; AlloNK gets FDA Fast Track for RA

Artiva Biotherapeutics, Inc.

2025-Q3 EPS reported -$2.59

Over 100 patients dosed with AlloNK; FDA Fast Track Designation for refractory RA with rituximab.
Initial response data for >15 refractory RA patients expected 1H 2026; FDA discussions planned.
Cash, equivalents, investments $123M as of Sep 30, 2025; runway into Q2 2027.
Q3 R&D expense $17.6M, G&A $5.3M; net loss $21.5M vs $17.5M year ago.
CFO Neha Krishnamohan to step down end of Dec, advisory role; successor search underway.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.